Insulet is Thursday's IBD Stock Of The Day. After a wild post-earnings reaction, Insulet stock is in a consolidation with an ...

Insulet Corporation (NASDAQ: PODD), best known for its Omnipod insulin delivery system, is emerging as a compelling ...

Insulet reported Omnipod revenue of $699.2 million for the third quarter of 2025, up 31% over the same quarter in 2024 ...

Insulet PODD continues to gain on solid prospects in the diabetes market. The company is progressing well with respect to its four-pillar strategy. Yet, its heavy reliance on the Omnipod System and a ...

Diabetes is a chronic health condition affecting blood glucose levels. In some cases, it requires constant management in the form of monitoring blood glucose levels and administering insulin.

Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...

Insulet is bringing a splash of color to the diabetes technology market. Working with Pantone, the insulin pump company has created the “bright and joyful tropical orange yellow” color Omnipod Mango.

Insulet Corporation recently reported strong third quarter results, with revenue and earnings surpassing analyst expectations and the company raising its full-year revenue and margin guidance. Key ...

Insulet stock rose moderately early Thursday as its insulin pump, Omnipod, delivered double-digit growth in the U.S. and ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...

The Omnipod 5 System consists of a tubeless wearable Pod, the Omnipod 5 mobile app, and the Dexcom G6 Continuous Glucose Monitoring System. The Food and Drug Administration (FDA) has cleared the ...